tirzepatide antibodies In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight AFP113-Tirzepatide
Pay in 4 interest-free payments of $5.92 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
![tirzepatide antibodies In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight AFP113-Tirzepatide](https://ecdn6.globalso.com/upload/p/1443/image_other/2026-03/biosimilar-antibodies-1-1.jpg)
![tirzepatide antibodies In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight AFP113-Tirzepatide](https://pbs.twimg.com/media/FjN368-WYAAXVyB.jpg)
![tirzepatide antibodies In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight AFP113-Tirzepatide](https://www.antibodysystem.com/storage/images/PHK13902-WB-1-Tirzepatide-antibodysystem.jpg)
![tirzepatide antibodies In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight AFP113-Tirzepatide](https://cdn.prod.website-files.com/62aec59ac7c1e4f6f1719e4a/6904b421d078f1c00be45261_QYCm6QEI_IFGxatIzIHATI4C44VQy137hYlaESU4npc.png)
![tirzepatide antibodies In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight AFP113-Tirzepatide](https://www.frontiersin.org/files/Articles/1747118/xml-images/fgstr-05-1747118-g001.webp)
![tirzepatide antibodies In an earlier analysis of the SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight AFP113-Tirzepatide](https://www.invivogen.com/sites/default/files/styles/wide/public/invivogen/media/image/Tirzepatide%20amino%20acid%20chain.png?itok=NhPDXaGP)






















